サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1362881

薬剤溶出ステントの市場規模、シェア、動向分析レポート：コーティングタイプ別、用途別、地域別、セグメント別予測、2023年～2030年

Drug Eluting Stent Market Size, Share & Trends Analysis Report By Coating Type (Polymer-based Coatings (Non-biodegradable, Biodegradable)), Polymer-free Coatings, By Application, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
薬剤溶出ステントの市場規模、シェア、動向分析レポート：コーティングタイプ別、用途別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月04日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

薬剤溶出ステント市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の薬剤溶出ステント市場規模は2030年までに136億5,000万米ドルに達し、予測期間中にCAGR 8.4％で成長すると予測されています。

人口の高齢化と、心血管疾患（CVD）、複雑病変、糖尿病、肥満などの危険因子の有病率の増加が、予測期間中に薬剤溶出ステントの需要を促進すると予想されています。さらに、コーティングやドラッグデリバリー機構の改良など、ステント設計の技術的進歩が進んでいるため、これらのデバイスの安全性と有効性が向上し、患者や医療従事者にとってより魅力的なものとなっています。

心血管系疾患の世界の有病率の増加が市場の需要に拍車をかけています。2022年の世界保健連合（WHF）の報告書によると、世界では5億人以上が引き続き心血管疾患に罹患しており、CVDは2021年に約2,050万人の死亡に寄与し、世界全体の死亡のほぼ3分の1を占めています。冠動脈疾患や末梢動脈疾患のような症状はますます一般的になっており、DESのような効果的な治療オプションに対する需要が急増しています。薬剤でコーティングされた表面を備えたこれらのステントは、患者に低侵襲のソリューションを提供し、再狭窄を効果的に防止して患者の転帰改善につながります。

薬剤溶出ステント市場は、COVID-19の大流行によって医療機器のサプライチェーンに混乱が生じ、大きな影響を受けた。すべての主要メーカーはCOVID-19との戦いに重点を置いていたため、他のセグメントの収益は大きな影響を受けた。冠動脈ステント市場の注目すべき競合他社はすべて、2020年に冠動脈ステントデバイスを含むインターベンショナルカーディオロジーポートフォリオの収益減少を発表したが、これは主にCOVID-19パンデミックの影響によるものです。

薬剤溶出ステント市場レポートハイライト

  • コーティングに基づくと、ポリマーベースコーティングセグメントが2022年に82.9%の圧倒的な収益シェアを占めました。このシェアは、ステント開発における広範な用途、ドラッグデリバリーにおける実証済みの有効性、さまざまな治療薬に対応できる汎用性などが、メーカーや医療関係者に好まれる理由と考えられます。さらに、ポリマーをベースとしたコーティング技術の継続的な進歩が、市場での主導的地位をさらに強固なものにしています。
  • 薬剤溶出ステント市場は、用途別に冠動脈疾患と末梢動脈疾患に分類され、2022年の売上シェアは前者が85.9%を占める。この成長は、世界的に冠動脈疾患の有病率が高く、薬剤溶出ステントのような効果的な治療オプションに対する大きな需要につながっていることに起因しています。
  • 北米地域は2022年に43.08%の最大の収益シェアを占め、予測期間を通じて市場を独占すると予想されます。北米は、病院を含むヘルスケアのインフラが発達しており、先進的です。さらに、同地域では心血管疾患の有病率が増加していることから、薬剤溶出ステントなどの効果的な治療オプションに対する需要が高まっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場動向と展望
  • 市場力学
    • 心血管疾患の有病率の増加
    • ステント設計における技術の進歩
    • 高齢者人口の増加
  • 市場抑制要因分析
    • 高コストの薬剤溶出ステント
  • 2022年の普及と成長の見通しマッピング
  • 事業環境分析
    • SWOT分析;要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 薬剤溶出ステント市場：コーティングタイプのセグメント分析

  • 薬剤溶出ステント：市場シェア分析、2022年および2030年
  • ポリマーベースコーティング
  • ポリマーフリーコーティング

第5章 薬剤溶出ステント市場：用途のセグメント分析

  • 薬剤溶出ステント：市場シェア分析、2022年および2030年
  • 冠動脈疾患
  • 末梢動脈疾患

第6章 薬剤溶出ステント市場：地域の分析

  • 薬剤溶出ステント市場シェア、地域別、2022年および2030年
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合情勢

  • 企業の分類
  • 戦略マッピング
  • 企業の市場シェア分析、2022年
  • 企業プロファイル・一覧表
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Terumo Corporation
    • Medtronic
    • Biosensors International
    • Cook Medical
    • B. Braun
    • Biotronik
    • Lepu Medical Technology
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 List of Secondary Sources

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Drug eluting stent market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market driver relevance analysis (Current & future impact)
  • Fig. 11 Market restraint relevance analysis (Current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global drug eluting stent market: Coating type movement analysis
  • Fig. 16 Global drug eluting stent market, for polymer-based coating, 2018 - 2030 (USD Billion)
  • Fig. 17 Global drug eluting stent market, for polymer-free coating, 2018 - 2030 (USD Billion)
  • Fig. 18 Global drug eluting stent market: Application movement analysis
  • Fig. 19 Global drug eluting stent market, for coronary artery disease, 2018 - 2030 (USD Billion)
  • Fig. 20 Global drug eluting stent market, for peripheral artery disease, 2018 - 2030 (USD Billion)
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 Regional outlook, 2022 & 2030
  • Fig. 23 Global drug eluting stent market: Regional movement analysis
  • Fig. 24 North America drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 25 U.S. drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 26 Canada drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 27 Europe drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 28 Germany drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 29 UK drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 30 France drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 31 Italy drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 32 Spain drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 33 Denmark drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 34 Sweden drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 35 Norway drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 36 Asia Pacific drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 37 Japan drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 38 China drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 39 India drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 40 Australia drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 41 South Korea drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 42 Thailand drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 43 Latin America drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 44 Brazil drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 45 Mexico drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 46 Argentina drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 47 Middle East and Africa drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 48 South Africa drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 49 Saudi Arabia drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 50 UAE drug eluting stent market, 2018 - 2030 (USD Billion)
  • Fig. 51 Kuwait drug eluting stent market, 2018 - 2030 (USD Billion)
目次
Product Code: 978-1-68038-999-9

Drug Eluting Stent Market Growth & Trends:

The global drug eluting stent market size is expected to reach USD 13.65 billion by 2030, advancing at a CAGR of 8.4% during the forecast period, according to a new report by Grand View Research, Inc.. An aging population and the increasing prevalence of risk factors such as cardiovascular diseases (CVDs), complex lesions, diabetes, obesity, and others are expected to drive the demand for drug eluting stents over the forecast period. Additionally, ongoing technological advancements in stent design, including improvements in coatings and drug delivery mechanisms, are enhancing the safety and efficacy of these devices, making them more appealing to patients and healthcare professionals.

The increasing prevalence of cardiovascular diseases globally has fueled market demand. According to the World Health Federation report in 2022, over half a billion people globally continue to be affected by cardiovascular diseases, with CVD contributing to approximately 20.5 million deaths in 2021, accounting for nearly a third of all deaths globally. Conditions like coronary artery disease and peripheral artery disease are becoming increasingly common, leading to a surge in demand for effective treatment options such as DES. These stents, equipped with drug-coated surfaces, offer patients a minimally invasive solution, effectively preventing restenosis and leading to improved patient outcomes.

The market for drug eluting stents was significantly impacted by the COVID-19 pandemic, with disruptions in the supply chain of medical devices. Since the focus of all major manufacturers was to fight the COVID-19 battle, the revenues of other segments were highly impacted. All notable competitors in the market for coronary stents announced a decline in revenue for their interventional cardiology portfolios, which include coronary stent devices in 2020, owing mostly to the impact of the COVID-19 pandemic.

Drug Eluting Stent Market Report Highlights:

  • Based on coating, the polymer-based coating segment held the dominant revenue share of 82.9% in 2022. This share can be attributed to its extensive usage in stent development, proven efficacy in drug delivery, and versatility in accommodating various therapeutic agents, making it a preferred choice for manufacturers and healthcare professionals alike. Additionally, continuous advancements in polymer-based coating technology have further solidified its leading position in the market
  • Based on application, the market for drug eluting stents has been categorized into coronary artery disease and peripheral artery disease, with the former accounting for 85.9% of the revenue share in 2022. The growth can be attributed to the high prevalence of coronary artery disease globally, leading to a substantial demand for effective treatment options such as drug eluting stents
  • The North American region held the largest revenue share of 43.08% in 2022 and is expected to dominate the market through the forecast period. North America has a well-developed and advanced healthcare infrastructure, including hospitals. Additionally, the increasing prevalence of cardiovascular diseases in the region has driven the demand for effective treatment options such as drug eluting stents

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information Or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing Prevalence of Cardiovascular Diseases
    • 3.4.2. Technological Advancements in Stent Design
    • 3.4.3. Growing Geriatric Population
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost of Drug Eluting Stents
  • 3.6. Penetration And Growth Prospect Mapping 2022
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Drug Eluting Stent Market: Coating Type Segment Analysis

  • 4.1. Drug Eluting Stent: Market Share Analysis, 2022 & 2030
  • 4.2. Polymer-Based Coating
    • 4.2.1. Polymer-Based Coating Market, 2018 - 2030 (USD Billion)
      • 4.2.1.1. Non-Biodegradable Polymers
      • 4.2.1.2. Biodegradable Polymers
  • 4.3. Polymer-free Coating
    • 4.3.1. Polymer-Free Coating Market, 2018 - 2030 (USD Billion)
      • 4.3.1.1. Micro Porous Surface
      • 4.3.1.2. Micro Structured Surface
      • 4.3.1.3. Slotted Tubular Surface
      • 4.3.1.4. Nanoporous Surface

Chapter 5. Drug Eluting Stent Market: Application Segment Analysis

  • 5.1. Drug Eluting Stent: Market Share Analysis, 2022 & 2030
  • 5.2. Coronary Artery Disease
    • 5.2.1. Coronary Artery Disease Market, 2018 - 2030 (USD Billion)
  • 5.3. Peripheral Artery Disease
    • 5.3.1. Peripheral Artery Disease Market, 2018 - 2030 (USD Billion)

Chapter 6. Drug Eluting Stent Market: Regional Analysis

  • 6.1. Drug Eluting Stent Market Share, By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. North Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Competitive Scenario
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. U.S. Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Canada Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
  • 6.3. Europe
    • 6.3.1. Europe Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. UK Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Germany Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. France Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Italy Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Spain Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Denmark Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Sweden Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Norway Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Japan Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. China Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. India Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.4.5. Australia
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Australia Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.4.6. Thailand
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Thailand Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.4.7. South Korea
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. South Korea Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
  • 6.5. Latin America
    • 6.5.1. Latin America Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Brazil Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.5.3. Mexico
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Mexico Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.5.4. Argentina
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Argentina Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
  • 6.6. MEA
    • 6.6.1. MEA Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. South Africa Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Saudi Arabia Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. UAE Drug Eluting Stent Market, 2018 - 2030 (USD Billion)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Kuwait Drug Eluting Stent Market, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Share Analysis, 2022
  • 7.4. Company Profiles/Listing
    • 7.4.1. Abbott Laboratories
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Boston Scientific Corporation
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Terumo Corporation
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Medtronic
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Biosensors International
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Cook Medical
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. B. Braun
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Biotronik
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Lepu Medical Technology
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives